Skip to main content
logo
Iambic Therapeutics, Inc. (IAM)
NASDAQ: IAM · Real-Time Price · USD
14.67
-1.13 (-7.15%)
At close: Oct 22, 2026, 4:00 PM EDT
14.30
-0.37 (-2.52%)
Pre-market: Oct 23, 2026, 5:05 AM EDT

Iambic Therapeutics Balance Sheet

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Cash & Equivalents
207.88180.54141.58
Cash & Short-Term Investments
207.88180.54141.58
Cash Growth
-27.52%-
Receivables
11.611.320.44
Prepaid Expenses
3.411.731.84
Total Current Assets
223.4183.59143.87
Property, Plant & Equipment
11.139.8510.52
Other Long-Term Assets
2.671.581.36
Total Assets
237.2195.02155.75

Liabilities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Accounts Payable
4.683.322.88
Accrued Expenses
10.710.086.31
Current Portion of Leases
0.820.770.75
Current Unearned Revenue
30.8811.316.64
Other Current Liabilities
1.550.810.31
Total Current Liabilities
48.6426.2916.89
Long-Term Leases
4.44.885.75
Long-Term Unearned Revenue
22.689.082.7
Total Liabilities
75.7240.2525.34

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Common Stock
0.020.020.02
Additional Paid-In Capital
12.688.575.61
Retained Earnings
-245.3-195.18-117.89
Comprehensive Income & Other
0.040.020.01
Total Common Equity
-232.56-186.56-112.25
Shareholders' Equity
161.48154.77130.41
Total Liabilities & Equity
237.2195.02155.75

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Total Debt
5.235.656.5
Net Cash (Debt)
202.65174.89135.08
Net Cash Growth
-29.47%-
Net Cash Per Share
9.188.096.31
Filing Date Shares Outstanding
23.6122.1321.42
Total Common Shares Outstanding
23.6122.1321.42
Working Capital
174.77157.3126.98
Book Value Per Share
-9.85-8.43-5.24
Tangible Book Value
-232.56-186.56-112.25
Tangible Book Value Per Share
-9.85-8.43-5.24
Machinery
10.438.697.43
Construction In Progress
0.61-0.06
Leasehold Improvements
0.030.030.07
SEC Filings: 10-K · 10-Q